Allied Investment Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 4.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 142,912 shares of the biopharmaceutical company’s stock after purchasing an additional 6,052 shares during the period. Pfizer comprises 2.4% of Allied Investment Advisors LLC’s portfolio, making the stock its 20th biggest position. Allied Investment Advisors LLC’s holdings in Pfizer were worth $7,399,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. State Street Corp increased its holdings in shares of Pfizer by 1.8% in the 4th quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock valued at $16,818,434,000 after acquiring an additional 5,013,651 shares during the period. Geode Capital Management LLC increased its holdings in shares of Pfizer by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company’s stock valued at $5,952,333,000 after acquiring an additional 1,471,980 shares during the period. Norges Bank purchased a new position in shares of Pfizer in the 4th quarter valued at $3,351,891,000. Nuveen Asset Management LLC increased its holdings in shares of Pfizer by 18.0% in the 4th quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company’s stock valued at $1,658,518,000 after acquiring an additional 4,278,167 shares during the period. Finally, UBS Asset Management Americas Inc. increased its holdings in shares of Pfizer by 2.0% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 23,728,801 shares of the biopharmaceutical company’s stock valued at $1,020,576,000 after acquiring an additional 457,513 shares during the period. 66.50% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Jennifer B. Damico sold 4,218 shares of the company’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the transaction, the senior vice president now directly owns 15,064 shares of the company’s stock, valued at approximately $760,732. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $2,075,003 in the last ninety days. 0.05% of the stock is currently owned by insiders.
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). The company had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same period last year, the firm earned $0.93 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 6.61 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Friday, May 13th were issued a $0.40 dividend. The ex-dividend date was Thursday, May 12th. This represents a $1.60 dividend on an annualized basis and a yield of 3.26%. Pfizer’s payout ratio is 36.70%.
Several brokerages recently weighed in on PFE. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a research note on Tuesday, May 3rd. Barclays set a $52.00 target price on Pfizer in a research note on Tuesday, May 17th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Wells Fargo & Company dropped their target price on Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. Finally, Morgan Stanley initiated coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.26.
Pfizer Company Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.